A Closer Look at Definium’s Phase 3 LSD for GAD Readout
This article analyzes the topline data from Definium Therapeutics' Phase 3 study of LSD (DT120) for Generalised Anxiety Disorder (GAD). It provides a closer look at the readout from this clinical trial.
By Evander · Published September 13, 2026
Sourced from psychedelicalpha.com, published August 26, 2026. Cite the original publication, not this page, for the reporting itself.
This article analyzes the topline data from Definium Therapeutics' Phase 3 study of LSD (DT120) for Generalised Anxiety Disorder (GAD). It provides a closer look at the readout from this clinical trial.